FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2362542081> ?p ?o ?g. }

• W2362542081 endingPage "603" @default.
• W2362542081 startingPage "599" @default.
• W2362542081 abstract "Study Objective Alkylating agents are implicated in premature ovarian insufficiency. To optimize counseling regarding future ovarian function in survivors of adolescent cancer, we describe anti-Müllerian hormone (AMH) levels in female adolescents at diagnosis, during, and shortly after completion of chemotherapy. Design, Setting, Participants, Interventions, and Main Outcome Measures This was a prospective single-institution study. Participants were a mixed population of newly diagnosed postmenarchal female adolescents with malignancy. AMH was performed at diagnosis (T1), 6 months from diagnosis (T2), at end of therapy or 12 months [T3, whichever came first], 1 year after the end of therapy or 24 months from diagnosis [T4, whichever came first], and 18 months from the time of diagnosis (T5). All patients had baseline pelvic ultrasound examinations. Presence of menses and hot flashes were recorded at each time point. Results Sixteen participants with a median age at diagnosis of 14.3 years (range 12-17 years) were followed for 18.2 months (range, 14-24 months). Oncology diagnoses included leukemia, lymphoma, and sarcoma. Ten patients (62.5%) received alkylating agents with a median cumulative dose of 3041 mg/m2 (range, 2639-6478 mg/m2) of cyclophosphamide. Almost half (n = 7; 44%) experienced amenorrhea during treatment with resumption of menses in 6 of 7 patients (85%). Fifteen of 16 (94%) participants showed a decline in mean AMH levels by 6 months (T2) from diagnosis (15.8 IU/mL at T1 vs 6.5 IU/mL at T2; P = .003) and 12 of 15 (80%) showed at least some recovery of AMH (mean AMH at T4 = 13.2 IU/mL compared with 6.5 IU/mL at T2; P = .02). There was no difference in the mean decline nor recovery of AMH in those who did, vs did not receive cyclophosphamide. Conclusion To our knowledge, this is the largest series to date in adolescents showing that AMH is uniformly suppressed during cancer therapy and short-term recovery occurs in just more than half of the patients by 18-24 months. The contribution of short-term AMH measurements in predicting long-term ovarian function remains to be defined. Long-term follow-up with serial AMH levels is required to help predict those at risk for premature ovarian insufficiency." @default.
• W2362542081 created "2016-06-24" @default.
• W2362542081 creator A5001915951 @default.
• W2362542081 creator A5002747929 @default.
• W2362542081 creator A5019168174 @default.
• W2362542081 creator A5025431226 @default.
• W2362542081 creator A5038846734 @default.
• W2362542081 creator A5041614674 @default.
• W2362542081 creator A5045168716 @default.
• W2362542081 creator A5076545515 @default.
• W2362542081 date "2016-12-01" @default.
• W2362542081 modified "2023-09-27" @default.
• W2362542081 title "Anti-Müllerian Hormone in Female Adolescent Cancer Patients Before, During, and After Completion of Therapy: A Pilot Feasibility Study" @default.
• W2362542081 cites W1926113458 @default.
• W2362542081 cites W1964979154 @default.
• W2362542081 cites W1970801031 @default.
• W2362542081 cites W1987571555 @default.
• W2362542081 cites W1994489910 @default.
• W2362542081 cites W2003583785 @default.
• W2362542081 cites W2015758016 @default.
• W2362542081 cites W2017241903 @default.
• W2362542081 cites W2041632361 @default.
• W2362542081 cites W2042592218 @default.
• W2362542081 cites W2059599357 @default.
• W2362542081 cites W2062221351 @default.
• W2362542081 cites W2082621216 @default.
• W2362542081 cites W2093974161 @default.
• W2362542081 cites W2107549312 @default.
• W2362542081 cites W2110539138 @default.
• W2362542081 cites W2117364932 @default.
• W2362542081 cites W2117706615 @default.
• W2362542081 cites W2119843778 @default.
• W2362542081 cites W2123533470 @default.
• W2362542081 cites W2128975535 @default.
• W2362542081 cites W2134989837 @default.
• W2362542081 cites W2140264607 @default.
• W2362542081 cites W2142720951 @default.
• W2362542081 cites W2143608188 @default.
• W2362542081 cites W2144504411 @default.
• W2362542081 cites W2147398079 @default.
• W2362542081 cites W2166037649 @default.
• W2362542081 cites W2166965101 @default.
• W2362542081 cites W2168491045 @default.
• W2362542081 cites W2168694309 @default.
• W2362542081 cites W2170901259 @default.
• W2362542081 cites W560471294 @default.
• W2362542081 doi "https://doi.org/10.1016/j.jpag.2016.04.009" @default.
• W2362542081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27184535" @default.
• W2362542081 hasPublicationYear "2016" @default.
• W2362542081 type Work @default.
• W2362542081 sameAs 2362542081 @default.
• W2362542081 citedByCount "19" @default.
• W2362542081 countsByYear W23625420812017 @default.
• W2362542081 countsByYear W23625420812018 @default.
• W2362542081 countsByYear W23625420812019 @default.
• W2362542081 countsByYear W23625420812020 @default.
• W2362542081 countsByYear W23625420812021 @default.
• W2362542081 countsByYear W23625420812022 @default.
• W2362542081 countsByYear W23625420812023 @default.
• W2362542081 crossrefType "journal-article" @default.
• W2362542081 hasAuthorship W2362542081A5001915951 @default.
• W2362542081 hasAuthorship W2362542081A5002747929 @default.
• W2362542081 hasAuthorship W2362542081A5019168174 @default.
• W2362542081 hasAuthorship W2362542081A5025431226 @default.
• W2362542081 hasAuthorship W2362542081A5038846734 @default.
• W2362542081 hasAuthorship W2362542081A5041614674 @default.
• W2362542081 hasAuthorship W2362542081A5045168716 @default.
• W2362542081 hasAuthorship W2362542081A5076545515 @default.
• W2362542081 hasConcept C121608353 @default.
• W2362542081 hasConcept C126322002 @default.
• W2362542081 hasConcept C141071460 @default.
• W2362542081 hasConcept C187212893 @default.
• W2362542081 hasConcept C2777904497 @default.
• W2362542081 hasConcept C2778058571 @default.
• W2362542081 hasConcept C2778311097 @default.
• W2362542081 hasConcept C2779234561 @default.
• W2362542081 hasConcept C2779399171 @default.
• W2362542081 hasConcept C2780275930 @default.
• W2362542081 hasConcept C2908647359 @default.
• W2362542081 hasConcept C518429986 @default.
• W2362542081 hasConcept C530470458 @default.
• W2362542081 hasConcept C54355233 @default.
• W2362542081 hasConcept C71924100 @default.
• W2362542081 hasConcept C86803240 @default.
• W2362542081 hasConcept C99454951 @default.
• W2362542081 hasConceptScore W2362542081C121608353 @default.
• W2362542081 hasConceptScore W2362542081C126322002 @default.
• W2362542081 hasConceptScore W2362542081C141071460 @default.
• W2362542081 hasConceptScore W2362542081C187212893 @default.
• W2362542081 hasConceptScore W2362542081C2777904497 @default.
• W2362542081 hasConceptScore W2362542081C2778058571 @default.
• W2362542081 hasConceptScore W2362542081C2778311097 @default.
• W2362542081 hasConceptScore W2362542081C2779234561 @default.
• W2362542081 hasConceptScore W2362542081C2779399171 @default.
• W2362542081 hasConceptScore W2362542081C2780275930 @default.
• W2362542081 hasConceptScore W2362542081C2908647359 @default.
• W2362542081 hasConceptScore W2362542081C518429986 @default.
• W2362542081 hasConceptScore W2362542081C530470458 @default.

• next